NewAmsterdam Pharma Co N.V. (NAMS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 10M 20M 30M Q1 '23: 8.6M Q2 '23: 1.7M Q3 '23: 2.9M Q4 '23: 803K Q1 '24: 1.4M Q2 '24: 2.3M Q3 '24: 29.1M Q4 '24: 12.8M Q1 '25: 3M Q2 '25: 19.1M Q3 '25: 348K Q4 '25: 32K Q1 '26: 3M Q2 '26: 3.7M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '23: -39.9M Q2 '23: -42.5M Q3 '23: -49.6M Q4 '23: -51.1M Q1 '24: -55.5M Q2 '24: -52.6M Q3 '24: -25M Q4 '24: -43.2M Q1 '25: -68.9M Q2 '25: -35.6M Q3 '25: -55.1M Q4 '25: -66M Q1 '26: -58.4M Q2 '26: -64.9M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '23: -42M Q2 '23: -38.3M Q3 '23: -47.1M Q4 '23: -49.5M Q1 '24: -93.8M Q2 '24: -39M Q3 '24: -16.6M Q4 '24: -92.2M Q1 '25: -39.5M Q2 '25: -17.4M Q3 '25: -72M Q4 '25: -74.9M Q1 '26: -48.4M Q2 '26: -64.1M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '23: -31.9M Q2 '23: -29.3M Q3 '23: -47M Q4 '23: -33.1M Q1 '24: -54.6M Q2 '24: -54M Q3 '24: -12.5M Q4 '24: -37.5M Q1 '25: -36.5M Q2 '25: -37.7M Q3 '25: -32.8M Q4 '25: -40.9M Q1 '26: -30.6M Q2 '26: -39.2M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '23: -31.9M Q2 '23: -29.3M Q3 '23: -47M Q4 '23: -33.1M Q1 '24: -55M Q2 '24: -54.2M Q3 '24: -12.6M Q4 '24: -37.5M Q1 '25: -36.5M Q2 '25: -37.8M Q3 '25: -32.8M Q4 '25: -41M Q1 '26: -30.6M Q2 '26: -39.3M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '23: 81.6M Q2 '23: 82.1M Q3 '23: 82.5M Q1 '24: 88.4M Q2 '24: 94.7M Q3 '24: 94.8M Q1 '25: 116.1M Q2 '25: 118.6M Q3 '25: 119M Q1 '26: 121.7M Q2 '26: 123.4M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q4 '23: -2.15 Q1 '24: -2.70 Q2 '24: -2.64 Q3 '24: -2.25 Q4 '24: -2.60 Q1 '25: -1.88 Q2 '25: -1.62 Q3 '25: -2.05 Q4 '25: -1.73 Q1 '26: -1.79 Q2 '26: -2.16 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.